We are a boutique investment banking / financial advisory firm headquartered in Shanghai. - Focusing on China’s emerging healthcare and related industries. - Specializing in cross-border transactions including M&A, Private placement and IPO. - Leveraging our combined expertise in finance, business development, healthcare industrial experiences and regulatory insights. - Established network with major industrial players, institutional investors and professional firms. - Offices in Shanghai, San Diego, London and Tel Aviv.
Location: China, Shanghai
Employees: 11-50
Mentions in press and media 5
| Date | Title | Description |
| 21.08.2024 | Bone Index and Lynx Financial: A Strategic Leap in Bone Health Diagnostics | In the world of medical technology, innovation is the lifeblood that keeps companies thriving. Bone Index Finland Ltd, a trailblazer in bone health diagnostics, has recently taken a significant step forward. The company announced a successf... |
| 20.08.2024 | Bone Index Announces Successful Financing Round and Strategic Partnership with Lynx Financial | KUOPIO, Finland, Aug. 20, 2024 /PRNewswire/ -- Bone Index Finland Ltd, a pioneering company in medical technology, proudly announces the completion of its latest financing round and a strategic partnership with Lynx Financial (HK) Limited. ... |
| 20.08.2024 | Bone Index Announces Successful Financing Round and Strategic Partnership with Lynx Financial | KUOPIO, Finland, Aug. 20, 2024 /PRNewswire/ -- Bone Index Finland Ltd, a pioneering company in medical technology, proudly announces the completion of its latest financing round and a strategic partnership with Lynx Financial (HK) Limited. ... |
| 04.04.2023 | Aurealis Therapeutics banks $10 million in an oversubscribed round | |
| 29.01.2022 | Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China | BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug... |